Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Gustavo Pereira has a total of 295 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Global Prognostic Impact of Substance Use in Alcohol‐Associated Hepatitis

    by Omar Albhaisi, Francisco Idalsoaga, Wei Wang, Roberta C. Araujo, Guilherme Massote Fontanini, Arun Valsan, Gowripriya Nair, Bastián Alcayaga, Jorge Arnold, María Ayala‐Valverde, et al.

    Background and Aims: Alcohol‐associated hepatitis (AH) carries high short‐term mortality. Although concomitant substance use is common in patients with AH, its impact on clinical outcomes remains unclear. We aimed to determine the prevalence of active substance use and evaluate its association with clinical outcomes in a large, multinational cohort of hospitalized patients with AH. Methods: We conducted a prospective, multicenter study across 38 centers in 13 countries (2015–2024). Adults meeting National Institute on Alcohol Abuse and Alcoholism (NIAAA) criteria for AH were enrolled. The primary outcome was all‐cause mortality stratified by substance use. Fine–Gray subdistribution hazard models were used to identify mortality predictors, with liver transplantation (LT) treated as a competing event. Results: We included 814 patients, with a mean age of 49.5 ± 10.6 years, and 88.8% were male. Active cannabis and cocaine use were reported in 6.1% and 5.5%, respectively. Over follow‐up, 210 patients (25.8%) died, and 35 (4.3%) underwent LT. In multivariable analysis, active cannabis use independently predicted higher mortality (sHR 2.49, 95% CI 1.52–4.09; p < 0.001), along with higher MELD scores and ACLF grades 2–3. Corticosteroid therapy (sHR 0.57, 95% CI 0.38–0.85; p = 0.007) and higher educational levels (sHR 0.34 and 0.31 for intermediate and highest categories, respectively) were associated with improved survival. Conclusions: Active substance use—particularly cannabis use—was independently associated with increased mortality in patients hospitalized with AH, even after adjusting for liver disease severity and accounting for transplantation as a competing event. These findings identify a behavioral dimension of AH severity and highlight the need to integrate addiction medicine and psychiatric care into hepatology practice to improve outcomes.

  • Open Access

    Impact of non-selective beta-blockers on acute kidney injury outcomes in patients with decompensated cirrhosis

    by Simone Incicco, Kavish R Patidar, Adrià Juanola, Ann T Ma, Anna Barone, Anand V Kulkarni, José Luis Pérez Hernández, Sumeet K Asrani, Brian Wentworth, Carlo Alessandria, et al.

  • Machine Learning Models Using Hospital Admission Characteristics Do Not Optimally Predict Nosocomial Infection Development in a Global Cirrhosis Cohort

    by Scott Silvey, Ashok K. Choudhury, Patrick S. Kamath, Qing Xie, Florence Wong, Peter C. Hayes, Wai-Kay Seto, Umang Arora, Garima Singhal, Dinesh Jothimani, et al.

    INTRODUCTION: Nosocomial infections (NIs) in cirrhosis are associated with high mortality but could be preventable. Logistic regression (LR) models have failed to identify high-risk patients. We aimed to develop machine learning (ML) models to predict NI. METHODS: The CLEARED consortium consists of prospectively enrolled cirrhosis inpatients from >120 centers. Using day-of-admission clinical data, 3 ML approaches (random forest [RF], extreme gradient boosting, and neural networks [NNs]) were used to predict NI. Data were split 80:20 for training and testing stratified by the outcome. Models were compared using area under the receiver operating characteristic curve (AUC). RESULTS: In total, 8,263 patients (55.90 ± 13.34 years; 64.1% men) from 127 centers in 37 countries were included. NI developed in 869 (10.5%), a median of 6 (4–11) days of postadmission. Major NIs were respiratory (29.6%) and urinary tract infection (15.7%), and spontaneous bacterial peritonitis (13.5%). NIs occurred more frequently in patients from low/low-middle income countries and those with severe liver disease, alcohol etiology, and admission infections. NIs were associated with inpatient mortality (31.9% vs 8.1%, P < 0.001) and liver transplantation (4.8% vs 1.9%, P < 0.001). Although the RF model (AUC 0.69) showed good calibration (Brier score 0.09), outperforming extreme gradient boosting, neural network, and LR models (AUC 0.66 for all; LR comparison P = 0.043), no model achieved AUC ≥0.80 for clinical utility. At 10% predicted probability threshold, the RF model demonstrated only 75.4% sensitivity, 52.9% specificity, and 15.9% positive predictive value (PPV). DISCUSSION: NIs cannot be accurately predicted from day-of-admission data using ML models, even in a large, prospective, global cirrhosis cohort. Every hospitalized patient with cirrhosis should receive protocolized infection control measures.

  • Acute kidney injury stage 1a increases mortality of patients with cirrhosis: a prospective multicenter cohort study

    by Ângelo Z. Mattos, Caroline Machado Rotta Dornelles, Leonardo de Lucca Schiavon, Liliana Sampaio Costa Mendes, Roberto José de Carvalho Filho, Liana Codes, Alberto Queiroz Farias, Mário Reis Álvares-Da-Silva, Carlos Terra, Gustavo Pereira, et al.

    Background and aims Acute kidney injury is a severe complication of cirrhosis. However, the impact of mild decreases in renal function is controversial. This study aims to evaluate the prognosis of the different stages of acute kidney injury in cirrhosis. Methods This is a multicenter prospective cohort study of patients hospitalized for acute decompensation of cirrhosis, with serum creatinine values measured at least twice. Primary outcome was mortality (in-hospital, 30 days, 90 days and 12 months). Results Nine hundred twenty-eight patients were included in the study. Acute kidney injury was diagnosed in 505 patients (stages 1a—21.6%, 1b—27.5%, 2—28.1%, 3—22.8%). Mortality rates of patients with acute kidney injury stage 1a were significantly higher than those of individuals without acute kidney injury (in-hospital—19.3% vs 4.7%; 30-day—21.8% vs 6.7%; 90-day—35.2% vs 17.5%; 12-month—54.1% vs 37.1%; p < 0.05 for all comparisons). Mortality rates were even higher for acute kidney injury stages 1b, 2 and 3. Survival analysis demonstrated that patients without acute kidney injury performed significantly better than those with any stage of acute kidney injury (p < 0.01). Acute kidney injury stages 1a, 1b, 2 and 3 were independently associated with survival in the multivariate analysis (p < 0.01). Conclusions Patients hospitalized for acute decompensation of cirrhosis who develop acute kidney injury have significantly higher mortality rates than those who do not develop this complication. This is true even for the mildest stages of acute kidney injury (stage 1a) and remains so at different time-points, supporting recommendations for earlier treatments. Graphical abstract


  • Open Access

    Severe thrombocytopenia in cirrhotic patients treated with Piperacillin-Tazobactam

    by Lívia Guimarães, Juliana Piedade, Tamires Rocha, Caroline Baldin, Lívia Victor, Gustavo Pereira


  • Open Access

    Natural History of Hepatosplenic Schistosomiasis (HSS) Non–Cirrhotic Portal Hypertension (NCPH): Influence of Gastrointestinal Bleeding and Decompensation in Prognosis

    by Zulane S. T. Veiga, Flávia F. Fernandes, Lívia Guimarães, Juliana Piedade, Gustavo Henrique S. Pereira

    Background: Hepatosplenic schistosomiasis (HSS) is a peculiar form of non-cirrhotic portal hypertension (NCPH). Although HSS patients present normal hepatic function, some evolve signs of hepatocellular failure and features of decompensated cirrhosis. The natural history of HSS-NCPH is unknown. Methods: A retrospective study was conducted that evaluated patients who fulfilled clinical-laboratorial criteria for HSS. Results: A total of 105 patients were included. Eleven patients already presented with decompensated disease and had lower transplant-free survival at 5 years than those without (61% vs. 95%, p = 0.015). Among 94 patients without prior decompensation, the median follow-up was 62 months and 44% of them had varicose bleeding (two or more episodes in 27%). Twenty-one patients presented at least one episode of decompensation (10-year probability 38%). Upon multivariate analysis, varicose bleeding and higher bilirubin levels were associated with decompensation. The 10-year probability of survival was 87%. Development of decompensation and age were predictive of mortality. Conclusion: HSS is characterized by multiple episodes of GI bleeding, a high probability of decompensation and reduced survival at the end of the first decade. Decompensation is more common in patients with varicose esophageal bleeding and is associated with lower survival.


  • Hepatic Encephalopathy in Cirrhotic Patients With Bacterial Infections: Frequency, Clinical Characteristics, and Prognostic Relevance

    by Lívia Guimarães, Juliana Piedade, Joana Duarte, Caroline Baldin, Lívia Victor, Barbara Costa, Zulane Veiga, Camila Alcântara, Flávia Fernandes, Gustavo Pereira


  • Open Access

    Results of interferon-free treatment for HCV-infected patients with decompensated cirrhosis from a Brazilian real-life cohort

    by Lívia Md Victor, Renata Perez, Flávia Fernandes, Juliana Md Piedade, Cristiane A. Villela-Nogueira, Gustavo Pereira

    Real-life data on the HCV treatment with direct-acting agents in patients with decompensated cirrhosis are scarce. Study to investigate the effectiveness and safety of sofosbuvir-containing regimens in a prospective cohort of patients with HCV decompensated cirrhosis. A total of 150 patients were enrolled (64% male, 84% genotype 1 with a mean age of 61 ± 9 years). The median MELD was 12, and 79% were Child-PughB. Most patients were treated with sofosbuvir and daclatasvir (98%) with ribavirin in 27%. The overall intention to treat SVR12 was 91% (137/150). The most frequent adverse event was anemia (17%), 73% associated with ribavirin. Twenty-one (14%) patients experienced renal dysfunction, 81% AKI I, and 1 discontinued treatment. Thirty-five (23%) patients presented at least 1 infectious episode, mainly respiratory tract infection (29%). Thirty-three patients (22%) had at least 1 episode of cirrhosis decompensation throughout treatment, particularly worsening of previous ascites in 19%. Nine patients died, and among those, 7 patients died from sepsis. The probability of decompensation in 28, 90 and 180 days was 4%, 19% and 25%. During treatment, infection (OR 2.24; 95 CI 1.09–4.61; P = .03) was a predictor of cirrhosis decompensation, and baseline MELD and CHILD ≥ B8 were both associated with infection. In decompensated cirrhosis, the overall virological response was high with mild adverse events. However, this population had a high frequency of liver-associated decompensation and infections.

  • Open Access

    Long-term survival and clinical outcomes following direct-acting antiviral (DAA) treatment in HCV decompensated cirrhosis in Brazil: a real-world study

    by Gustavo H. Pereira, Helena R. Peixoto, Mariana L. Giusti, Mariana L. Souza, Livia B. Victor, Flávia Fernandes, Renata M. Perez, Cristiane A. Villela-Nogueira


  • Frequency and predictive factors of minimal hepatic encephalopathy before and after sustained virological response in HCV cirrhosis

    by Juliana Piedade, Livia Guimarães, Joana Duarte, Lorena Gouveia, Tamar Garfinkel, Zulane Veiga, Camila Alcântara, Hugo Perazzo, Flavia Fernandes, Gustavo Pereira

    Introduction Data of minimal hepatic encephalopathy (MHE) before and after hepatitis C virus (HCV) treatment remain scarce. We aimed to describe the prevalence, evolution and predictive factors of MHE before and after a sustained virological response (SVR). Material and methods It was a...